IDEAYA Biosciences

IDYA · NASDAQ

$35.36+$1.55 (+4.58%)TodayMarket closed ·
Prev close $33.81

About IDYA

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 145 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.

Employees
145
Headquarters
South San Francisco, California
Listed
May 23, 2019
Sector
Health Care
Industry
Biotechnology

Leadership

IDEAYA Biosciences executives
NameTitleSince
Terry Rosen——
Yujiro Hata—2015
Joshua Bleharski——
Andres Briseno——
Michael White——
Darrin Beaupre——
Stuart Dorman——
Theodora Ross——
M. Garret Hampton——
Catherine Mackey——
Scott Morrison——
Jeffrey Stein——
Wendy Yarno——

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

IDEAYA Biosciences suppliers and customers
CompanyRelationshipCorrelation
WuXi AppTec Co HSupplier and customer0.80
Roche Holding ROG.SWSupplier and customer-0.15
Novartis NOVN.SWSupplier and customer-0.32
Pfizer PFESupplier and customer-0.35
GlaxoSmithKline GSK.LSupplier and customer-0.70
Cyteir Therapeutics CYTSupplier—
Cancer Research UKSupplier and customer—
University of ManchesterSupplier and customer—
Broad Institute, Inc.Supplier and customer—
University of California San DiegoSupplier and customer—

Similar companies

Companies in the same industry as IDEAYA Biosciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.